Know the Pros and Cons of Lecanemab for Alzheimer Disease

January 2026

You’ll hear buzz about a new Alzheimer med, lecanemab (Leqembi).

It’s an IV monoclonal antibody for mild cognitive impairment or mild dementia due to early Alzheimer disease.

Lecanemab works by reducing a protein in the brain called amyloid beta. Buildup of this protein in the brain is thought to cause Alzheimer disease.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Obesity & Weight Loss Listen for New Side Effect Concerns With GLP-1 Agonists
Pediatrics Be Aware of the Role of Jornay PM for ADHD
Hair Loss Untangle Mix-Ups With Meds for Male Pattern Baldness
Pediatrics Stay Alert for Meds on the “KIDs List” to Keep Children Safe
Biologics Be Familiar With the Laundry List of Uses for Dupilumab
Education and Training Weave AI Into Your Plan for Training Learners
Alzheimer Disease Know the Pros and Cons of Lecanemab for Alzheimer Disease
NatMed Spotlight Methylene Blue: Evidence Review